Northern Trust Corp increased its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 7.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 912,713 shares of the technology company's stock after purchasing an additional 65,415 shares during the quarter. Northern Trust Corp owned approximately 0.83% of Cogent Biosciences worth $7,119,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of COGT. FMR LLC lifted its position in shares of Cogent Biosciences by 99.2% during the fourth quarter. FMR LLC now owns 16,569,256 shares of the technology company's stock worth $129,240,000 after acquiring an additional 8,249,845 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Cogent Biosciences by 7.3% during the 4th quarter. Vanguard Group Inc. now owns 6,133,380 shares of the technology company's stock worth $47,840,000 after purchasing an additional 418,975 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Cogent Biosciences by 5.8% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 4,300,000 shares of the technology company's stock worth $33,540,000 after purchasing an additional 233,966 shares in the last quarter. Geode Capital Management LLC boosted its stake in Cogent Biosciences by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 2,308,509 shares of the technology company's stock worth $18,011,000 after purchasing an additional 27,716 shares during the period. Finally, Franklin Resources Inc. grew its holdings in Cogent Biosciences by 28.3% during the 4th quarter. Franklin Resources Inc. now owns 1,283,673 shares of the technology company's stock valued at $10,013,000 after buying an additional 283,506 shares in the last quarter.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. HC Wainwright lowered their price target on shares of Cogent Biosciences from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Tuesday, May 20th. Robert W. Baird lowered their target price on shares of Cogent Biosciences from $8.00 to $7.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Wedbush reissued a "neutral" rating and issued a $11.00 price target on shares of Cogent Biosciences in a report on Tuesday, February 25th. Needham & Company LLC reaffirmed a "hold" rating on shares of Cogent Biosciences in a report on Wednesday, February 26th. Finally, Scotiabank initiated coverage on Cogent Biosciences in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $17.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Cogent Biosciences has an average rating of "Moderate Buy" and an average target price of $14.00.
View Our Latest Analysis on Cogent Biosciences
Cogent Biosciences Price Performance
NASDAQ COGT traded down $0.13 during trading hours on Friday, hitting $4.82. The company's stock had a trading volume of 877,172 shares, compared to its average volume of 1,262,944. The company's 50 day simple moving average is $5.18 and its two-hundred day simple moving average is $7.26. The company has a market cap of $548.79 million, a P/E ratio of -1.94 and a beta of 1.91. Cogent Biosciences, Inc. has a 12 month low of $3.72 and a 12 month high of $12.61.
Cogent Biosciences (NASDAQ:COGT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The technology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.04. As a group, research analysts predict that Cogent Biosciences, Inc. will post -2.42 earnings per share for the current fiscal year.
About Cogent Biosciences
(
Free Report)
Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
See Also
Before you consider Cogent Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cogent Biosciences wasn't on the list.
While Cogent Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
